Media headlines about MEI Pharma (NASDAQ:MEIP) have trended somewhat positive on Friday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MEI Pharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1508949819926 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of MEI Pharma (MEIP) traded down 0.76% during mid-day trading on Friday, reaching $2.62. The company’s stock had a trading volume of 215,850 shares. The firm’s 50 day moving average is $2.80 and its 200-day moving average is $2.08. MEI Pharma has a 52-week low of $1.34 and a 52-week high of $3.26. The company has a market capitalization of $96.34 million, a PE ratio of 77.06 and a beta of 1.56.

Several research firms have recently commented on MEIP. Cann restated a “buy” rating and set a $6.50 price target on shares of MEI Pharma in a research note on Monday, June 26th. Oppenheimer Holdings, Inc. set a $7.00 price objective on MEI Pharma and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Finally, Zacks Investment Research upgraded MEI Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Wednesday, July 19th.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at

MEI Pharma Company Profile

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Insider Buying and Selling by Quarter for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.